Clinical trials: Apathy in Dementia
Apathy, Huntington's Disease
Apathy Cure Through Bupropion in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in…
- Trial name
- Action-HD (NCT01914965)
- Testing
- Bupropion
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Dementia, Accidental Falls
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
Falls in the elderly are a very common and serious health problem with devastating consequences. Those with dementia are 5 times more likely to experience falls than older people without significant cognitive impairment.
- Conditions
- Dementia, Accidental Falls, Apathy
- Trial name
- NCT01825577
- Testing
- Transdermal Methylphenidate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Louis University
Emotions, Dementia
Dementia Associated Apathy.
We want to determine if patients with dementia show any kind of emotion while they look at a defined selection of photos. These are photos taken from a international image-platform and mixed with photos (biographic) that show…
- Conditions
- Emotions, Dementia, Apathy
- Trial name
- NCT03293537
- Testing
- Skin conductance and Heart rate measurement
- Where
- Switzerland
- Volunteers
- 133 people
- Sponsor
- Zurich University of Applied Sciences
Alzheimer Disease
Assessment of Sleep Disturbance in Alzheimer Disease
The purpose of this study is to study circadian rhythms, or daily cycles of sleep, wake, and activity. The investigators hope to learn how disturbed sleep in Alzheimer's Disease relates to changes in activity cycles, and how…
- Trial name
- NCT00831298
- Testing
- Analysis of sleep disturbance
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS
Dementia, Alzheimer's Disease
Virtual Reality Intervention for the Reduction of Behavioral and Psychological Symptoms of Dementia
Alzheimer's disease and related disorders (AD2) are characterised by cognitive changes and Behavioural and Psychological Symptoms of Dementia (BPSD).
- Conditions
- Dementia, Alzheimer's Disease, Neurocognitive Disorders
- Trial name
- LUMEENCOMPAD (NCT04769024)
- Testing
- LUMEEN Virtual Reality sessions, Control/non-digital stimulation sessions
- Where
- 6 sites in France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Huntington Disease
Impact of Apathy on Caregiving in HD. Version 1
Huntington's disease (HD) can affect motivation. People with HD may not wash often, keep their house clean and tidy, or eating healthy food.
- Trial name
- NCT05913154
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Alzheimer's Disease, Apathy
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia.
- Conditions
- Alzheimer's Disease, Apathy, Dementia
- Trial name
- NCT00495820
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Behavioral Disorder
Evaluation of the Effectiveness of the TOVERTAFEL System on Behavioral Disorders
The prevalence of behavioral disorders is high in patients living in an institutional environment or hospitalized in a long-term care unit.
- Trial name
- TOVERTAFEL (NCT04421833)
- Testing
- TOVERTAFEL, USUAL activities
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Hospices Civils de Lyon
Dementia, Alzheimer Disease
Apathy Associated With Alzheimer's Disease
Apathy, or lack of motivation, affects up to 80% of Alzheimer's disease (AD) patients. These amotivational symptoms increase patient reliance on caregivers, increase caregiver burden and distress, and increase the risk of patient…
- Trial name
- NCT00254033
- Testing
- Dextroamphetamine, Methylphenidate
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Apathy, Alzheimer's Disease
Apathy in Dementia Methylphenidate Trial 2
Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with…
- Trial name
- ADMET2 (NCT02346201)
- Testing
- Methylphenidate
- Where
- 10 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Alzheimer Disease, Apathy in Dementia
rTMS for Apathy Clinical Trial
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm.
- Conditions
- Alzheimer Disease, Apathy in Dementia, Dementia, Mild Behavioural Impairment
- Trial name
- REACT (NCT05561205)
- Testing
- rTMS, methylphenidate
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Apathy in Dementia
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.
- Trial name
- NCT04958031
- Testing
- CVL-871 1.0 mg, CVL-871 3.0 mg
- Where
- 20 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- AbbVie
Apathy in Dementia
Bupropion for the Treatment of Apathy in Alzheimer's Dementia
Apathy in dementia prevents successful application of non-pharmacological treatments, accelerates cognitive and functional decline and increases disease-related costs by earlier need for full-time care.
- Trial name
- APA-AD (NCT01047254)
- Testing
- Elontril
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University Hospital, Bonn
Alzheimer Disease
Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)
The purpose of this study is to assess acceptability, and safety of providing tDCS to ADRD patients with behavioral symptoms and to assess the efficacy of tDCS for ADRD-related symptoms, mainly behavioral symptoms.
- Trial name
- NCT05478681
- Testing
- active tDCS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Apathy, Alzheimer's Dementia
Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia
Alzheimer's Dementia (AD) is a major public health problem. Apathy, a profound loss of motivation, is seen in majority of patients with AD.
- Trial name
- NCT02190084
- Testing
- Neurostar repetitive transcranial magnetic stimulator
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Central Arkansas Veterans Healthcare System
Dementia, Cognitive Impairment
Effective Strategies for Dementia Care
The purpose of this study is to determine whether the interventions of Snoezelen, structured reminiscence therapy and 10-minutes activation are effective to reduce apathy in long term care residents with dementia.
- Trial name
- WISDE (NCT00653731)
- Testing
- Snoezelen ©, structured reminiscence therapy, 10-minutes activation
- Where
- Germany
- Volunteers
- 327 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Apathy, Alzheimer's Disease
Apathy in Dementia Methylphenidate Trial (ADMET)
The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial that will examine the efficacy and safety of methylphenidate for the treatment of clinically significant apathy in patients with…
- Trial name
- ADMET (NCT01117181)
- Testing
- Methylphenidate, Psychosocial intervention
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD)
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
Apathy is defined as a quantitative reduction in voluntary and goal-directed behavior. To address this, the investigators propose an ethological approach to assess apathy objectively and quantitatively by observing patients in…
- Conditions
- Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD), Disinhibition, Depression - Major Depressive Disorder
- Trial name
- ECOCAPTURE (NCT03272230)
- Testing
- ECOCAPTURE, Cognitive and Behavioral experimental tasks, Neuropsychological assessment
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Quality of Life
Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy
Improving quality of life (QoL) in residents of nursing homes: A cluster randomized clinical trial of efficacy - The KOSMOS study.
- Trial name
- KOSMOS (NCT02238652)
- Testing
- Communication, Systematic Pain Assessment and Treatment, Medication Review
- Where
- 32 sites in Norway
- Volunteers
- 560 people
- Sponsor
- University of Bergen